Contrast developer Mallinckrodt of St. Louis has started the first U.S. shipments of its NeutroSpec radiopharmaceutical.
NeutroSpec is a monoclonal antibody agent labeled with technetium (99m-Tc) fanolesomab. It is designed to help diagnose cases of appendicitis in patients five years and older with atypical symptoms, according to Mallinckrodt. The product was developed by Mallinckrodt's corporate partner Palatin Technologies of Cranbury, NJ.
NeutroSpec is available through Mallinckrodt's nuclear pharmacy network in the U.S., as well as the nuclear pharmacy network operated by Cardinal Health Nuclear Pharmacy Services of Woodland Hills, CA.
By AuntMinnie.com staff writers
August 20, 2004
Related Reading
Palatin receives milestone payment, August 6, 2004
Mallinckrodt, Palatin get FDA approval, July 6, 2004
Palatin nets $22.7 million, January 30, 2004
Palatin raises $19 million, April 1, 2003
Mallinckrodt gets FDA nod for MR contrast power injection, March 18, 2003
Copyright © 2004 AuntMinnie.com
